This is a Proprietary Laboratory Analyses (PLA) code, meaning that the code applies to only one unique lab test made by a specific manufacturer or performed by a specific lab. Report 0467U only for UroAmp MRD from Convergent Genomics Inc. This test for bladder cancer uses next–generation sequencing (NGS) to analyze 60 specific genes and the entire genome for aneuploidy (abnormal number of chromosomes) from a urine sample. The test results, processed through advanced algorithms, provide the minimal residual disease (MRD) status, which is reported as either positive or negative, and the quantitative disease burden, which measures the amount of cancer present.
For clinical responsibility, terminology, tips and additional info
start codify free trial.